Association of dyslipidemia and effects of statins on nonmacrovascular diseases

Baghdasarian, Sarkis B.; Jneid, Hani; Hoogwerf, Byron J.

doi:10.1016/s0149-2918(04)90031-8

Cited by 22 publications

(12 citation statements)

References 120 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 Atorvastatin therapy in type 2 diabetics with dyslipidaemia has been shown to reduce the severity of hard exudates and subfoveal lipid migration in clinically significant macularoedema in patients with diabetic macular oedema in conjunction with laser photocoagulation. 5 A small clinical trial of six patients (11 eyes) demonstrated reduced retinal hard exudates with pravastatin treatment in patients with diabetic CASE REPORT 6 The association between serum lipid levels and diabetic retinopathy has been investigated in many studies. Some studies show a positive relationship between serum cholesterol and low-density lipoprotein levels and retinal exudation.…”

Section: Discussionmentioning

confidence: 99%

“…Following the advent of systemic lipid lowering therapy over the last decade there is a potential for medical therapy. 5,6 The benefits of statins have been clearly photographed in patients with exudative maculopathy. 7 We have further quantified the effect of statins on diabetic maculopathy by using OCT. We report four patients, commenced on statins, who showed both resolution of exudates photographically and a reduction of retinal thickness and hence macular oedema as measured comparatively by OCT.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Quantifying changes in retinal anatomy after interventions for diabetic maculopathy

Soomro

Burnett²,

Davies³

2007

Diabetes & Vascular Disease

View full text Add to dashboard Cite

Introduction D iabetic maculopathy remains the major cause of loss of vision in diabetes. There is evidence to show that control of lipid levels reduces the amount of exudate in diabetic maculopathy, but to date there is no information on the effect of lipid reduction on diabetic macular oedema. PurposeThe purpose of this case series was to compare retinal thickness using optical coherence tomography (OCT) of patients with exudative diabetic maculopathy whose only change in management was starting statins or increasing the current dose. Methods Four patients with exudative diabetic maculopathy had serial OCT measurements to assess retinal thickness before and after commencing or increasing their statin dose. ResultsAnalysis showed a reduction of macula thickness in all cases. Visual acuity also improved during the time course of the measurements. ConclusionStatins may aid management of diabetic maculopathy by reducing macular oedema. This case series gives the first quantified evidence of the effect of statins on reduction of diabetic macular oedema. Br J Diabetes Vasc Dis 2007;7:181-5

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Quantifying changes in retinal anatomy after interventions for diabetic maculopathy

Soomro

Burnett²,

Davies³

2007

Diabetes & Vascular Disease

View full text Add to dashboard Cite

show abstract

“…Data from cohort study of patients with bilaterial large drusen within a multicenter, randomised, clinical trial are not consistent with a strong protective effect (risk ratio, ≤ 0.85) of statins on the development of advanced AMRD among these patients (Maguire et al, 2009). Baghdasarian et al (2004) (Etminan et al, 2008). Observational studies evaluating treatment effects are subject to range of biases due to heterogeneity of findings.…”

Section: Statins and Incidence Of Age-related Macular Degenerationmentioning

confidence: 99%

Therapeutic Potential of Statins in Age-related Macular Degeneration

Shahsuvaryan¹

2011

Sierra Leone j. biomed. res.

View full text Add to dashboard Cite

Age-related macular degeneration (ARMD) is the leading cause of irreversible vision loss, affecting one in three people aged 75 and above. Although exciting new pharmaceuticals to treat ARMD such as endothelial growth factor (VEGF) inhibitors, are now available, they are effective only in selected group of patients, and can be used only during a narrow time window. Monthly intravitreal anti-VEGF injections with systemic exposure to anti-VEGF could be replaced by new drugs taken in a non-invasive way. Statins are the most commonly used lipid lowering drugs. The objective of this review is therefore to evaluate the evidence and discuss the rationale behind the recent suggestions that statins may be useful in the prevention and the treatment of age-related macular degeneration. This review recognised that there are potentially multiple biological bases for the protective effect of statins on the risk of ARMD. Thus, it is time to conduct a randomised controlled trial to provide direct evidence of the effectiveness of specific type statin in lowering the incidence and progression of ARMD. New intervention as statins usage to prevent the development of age-related macular degeneration and its progression remain an important strategy to limit the morbidity due to this significant public health problem.

show abstract

“…Given the strong potential link between atherosclerosis and aortic stenosis [20,45,[46][47][48][49] a number of clinical trials began to explore the role that antiatherosclerotic medications may play in the management of aortic stenosis [50]. Retrospective analyses of cohort studies suggested that statins would be beneficial in aortic stenosis [21].…”

Section: Drug Treatment Of Aortic Stenosismentioning

confidence: 99%